With the increasing popularity of vertebroplasty, a minimally invasive procedure for treating vertebral compression fractures, reports of multiple patient deaths are beginning to surface. While not related to the products from companies developing delivery systems and/or new materials for vertebroplasty, such as Kyphon Inc. , Orthovita Inc. , and American OsteoMedix Corp. (AOM), which in May merged with spinal implant maker Interpore Cross International Inc.[See Deal], the issue is one they must squarely face as they develop clinical data to support their products.
For years, surgeons ignored compression fractures, a particular problem in osteoporotic women, because intervention in those patients was risky, and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?